Biohaven BHVN Stock
Biohaven Price Chart
Biohaven BHVN Financial and Trading Overview
| Biohaven stock price | 17.2 USD |
| Previous Close | 15.06 USD |
| Open | 15.29 USD |
| Bid | 0 USD x 100 |
| Ask | 16 USD x 500 |
| Day's Range | 14.88 - 15.29 USD |
| 52 Week Range | 12.79 - 55.7 USD |
| Volume | 1.22M USD |
| Avg. Volume | 2.07M USD |
| Market Cap | 1.56B USD |
| Beta (5Y Monthly) | 3.498 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.46 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.21 USD |
BHVN Valuation Measures
| Enterprise Value | 1.27B USD |
| Trailing P/E | N/A |
| Forward P/E | -2.40981 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.9937034 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.403 |
Trading Information
Biohaven Stock Price History
| Beta (5Y Monthly) | 3.498 |
| 52-Week Change | -60.85% |
| S&P500 52-Week Change | 18.63% |
| 52 Week High | 55.7 USD |
| 52 Week Low | 12.79 USD |
| 50-Day Moving Average | 14.71 USD |
| 200-Day Moving Average | 29.65 USD |
BHVN Share Statistics
| Avg. Volume (3 month) | 2.07M USD |
| Avg. Daily Volume (10-Days) | 2.3M USD |
| Shares Outstanding | 102.11M |
| Float | 84.7M |
| Short Ratio | 7.32 |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 87.93% |
| Shares Short | 13.48M |
| Short % of Float | 14.91% |
| Short % of Shares Outstanding | 13.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -129.99% |
| Return on Equity (ttm) | -316.82% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -903876992 USD |
| Net Income Avi to Common (ttm) | -888595008 USD |
| Diluted EPS (ttm) | -9.25 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 322.75M USD |
| Total Cash Per Share (mrq) | 3.16 USD |
| Total Debt (mrq) | 35.51M USD |
| Total Debt/Equity (mrq) | 13.69 USD |
| Current Ratio (mrq) | 2.333 |
| Book Value Per Share (mrq) | 2.541 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -644940032 USD |
| Levered Free Cash Flow (ttm) | -394098496 USD |
Profile of Biohaven
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 215 Church Street |
| ZIP | 06510 |
| Phone | 203 404 0410 |
| Website | https://www.biohaven.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 256 |
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Q&A For Biohaven Stock
What is a current BHVN stock price?
Biohaven BHVN stock price today per share is 17.2 USD.
How to purchase Biohaven stock?
You can buy BHVN shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biohaven?
The stock symbol or ticker of Biohaven is BHVN.
Which industry does the Biohaven company belong to?
The Biohaven industry is Biotechnology.
How many shares does Biohaven have in circulation?
The max supply of Biohaven shares is 105.79M.
What is Biohaven Price to Earnings Ratio (PE Ratio)?
Biohaven PE Ratio is now.
What was Biohaven earnings per share over the trailing 12 months (TTM)?
Biohaven EPS is -7.46 USD over the trailing 12 months.
Which sector does the Biohaven company belong to?
The Biohaven sector is Healthcare.
Biohaven BHVN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech US 700 Small Cap Index NQUS700SC | 2566.34 USD — |
+0.47
|
— — | 2546.3 USD — | 2571.79 USD — | — - | — — |
| NYSE Composite Index NYA | 21459.58 USD — |
+0.04
|
— — | 21350.03 USD — | 21510.64 USD — | — - | — — |
- {{ link.label }} {{link}}